Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorWashington University School of Medicine
About this trial
Advanced cervical cancer patients treated with standard of care (SOC) chemoradiation plus glutaminase inhibition with telaglenastat (CB-839) will have increased progression-free survival (PFS) compared to historical rates for patients receiving SOC chemoradiation alone.
Eligibility criteria
Qualifiers
Patient age ≥ 18 years.
Patients with histologically confirmed newly diagnosed advanced cervical cancer (squamous, adenosquamous, adenocarcinoma or poorly differentiated); Federation of Gynecology and Obstetrics (FIGO) 2018 clinical stages III-IVA.
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Absolute neutrophil count ≥ 1,500/mcL.
Disqualifiers
Patient has another concurrent active invasive malignancy.
Patient has received prior radiation therapy to the pelvis or previous therapy of any kind for this malignancy, or pelvic radiation for any prior malignancy.
Patient is receiving another investigational agent for the treatment of cancer.
Poorly controlled diabetes, with inability to perform 18F-FDG PET scan.
Trial design
Treatments tested in this trial
- Telaglenastat
- Radiation treatment
- Cisplatin
Treatment groups
42 Participants
are divided into 2 treatment groupsSponsors and collaborators
Washington University School of Medicine
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Calithera Biosciences, Inc
Collaborator
Source ClinicalTrials.gov